Share ownership OncoSil Medical Limited

OSL

AU000000OSL3

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 01:31:03 2024-09-09 am EDT			5-day change	1st Jan Change
0.0130 ^AUD	+8.33%		+8.33%	+44.44%

Aug. 30	OncoSil Medical Limited Appoints Peter Hall as Non-Executive Director	CI
Aug. 30	OncoSil Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2024	CI

Share class: OncoSil Medical Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	3,332,109,580	3,194,172,470 ( 95.86 %)	0	95.86 %

Major shareholders: OncoSil Medical Limited

Name	Equities	%	Valuation
Washington H. Soul Pattinson & Co. Ltd. (Invt Mgmt) 10.19 %	385,714,286	10.19 %	3 M $

Breakdown by shareholder type

Institutional	10.19%
Unknown	89.81%

Based on 1000 largest holdings

Geographical origin of shareholders

Australia

10.19%

Based on 1000 largest holdings

OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.

Employees

Sector

Pharmaceuticals

Calendar

2024-09-17 - Extraordinary Shareholders Meeting

More about the company